NTRK fusion positive cancer
MONDO:0700215Neoplasm associated with the expression of a Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion. NTRK fusion-positive tumors have been identified in a broad range of solid tumor types, including breast, cholangiocarcinoma, colorectal, gynecological, neuroendocrine, non-small cell lung, salivary gland, pancreatic, sarcoma and thyroid cancers.
Also known as: NTRK fusion positive neoplasm, NTRK fusion positive solid tumor, NTRK fusion positive solid tumour, neurotrophic tyrosine receptor kinase fusion positive cancer, neurotrophic tyrosine receptor kinase fusion positive neoplasm, neurotrophic tyrosine receptor kinase fusion positive solid tumor, neurotrophic tyrosine receptor kinase fusion positive solid tumour
1450 clinical trials for this condition and its sub-types, 19 tagged with NTRK fusion positive cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New hope for kids with rare cancers: targeted drug repotrectinib enters trial
Disease control Recruiting nowThis study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors, lymphoma, or brain tumors that have specific gene changes (ALK, ROS1, or NTRK1-3). The goal is to find the safest dose and see if the drug shrinks tumors. Particip…
Phase 1/2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a targeted drug be safely used in children with rare tumors?
Disease control Recruiting nowThis study monitors the safety of repotrectinib, a targeted cancer drug, in children and adolescents aged 4 to under 18 with NTRK fusion-positive advanced or recurrent solid tumors. Researchers will track side effects during routine treatment, paying special attention to nervous …
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo aims to shrink tough lung cancers
Disease control Recruiting nowThis Phase 2 trial tests a drug called ivonescimab, either alone or with chemotherapy, in people with advanced non-small cell lung cancer that has certain genetic changes. The study aims to see if the treatment can shrink tumors and control the cancer. About 46 participants will …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New study tracks Larotrectinib's Real-World impact on rare cancers
Disease control Recruiting nowThis study looks at how well larotrectinib works and how safe it is for people with advanced or returning TRK fusion cancer. It includes both adults and children whose cancer has spread or come back. Researchers will collect information from medical records and doctor visits to s…
Sponsor: Bayer • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…
Phase 1/2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New pill targets rare cancer gene in 60-Patient trial
Disease control Recruiting nowThis phase 2 trial is testing a drug called TL118 in 60 adults with advanced solid tumors that have a specific genetic change called an NTRK gene fusion. The drug is taken by mouth and aims to shrink tumors or stop them from growing. The study is currently recruiting participants…
Phase 2 • Sponsor: Teligene US • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for rare cancers: first human trial of ANS03 begins
Disease control Recruiting nowThis early-phase study tests a new drug called ANS03 in adults with advanced solid tumors that have specific gene changes (ROS1 or NTRK). The main goals are to check safety and find the right dose. About 96 participants will receive the drug, and doctors will monitor side effects…
Phase 1 • Sponsor: Avistone Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New pill targets rare gene faults in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called CG001419 in adults with advanced solid tumors that have certain NTRK gene changes. The trial has two parts: first, finding a safe dose and checking for side effects; second, seeing if the drug can shrink tumors. About 42 people will ta…
Phase 1/2 • Sponsor: Cullgen (Shanghai),Inc • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called VMD-928, taken as a pill, either alone or with another cancer drug (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have not responded to or are no longer controlled by available treatments. The goal is to …
Phase 1/2 • Sponsor: VM Oncology, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill targets rare genetic cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called ICP-723 in people with advanced solid tumors or primary central nervous system tumors that have a specific genetic change called NTRK fusion. The drug is taken as a tablet once daily. The main goal is to see how many patients' tumors s…
Phase 1/2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:14 UTC
-
New study tracks how well larotrectinib works in everyday cancer care
Knowledge-focused Recruiting nowThis study follows 150 adults and children with advanced TRK fusion cancers who are already taking the drug larotrectinib (Vitrakvi). Researchers will collect data from routine doctor visits over 2 to 5 years to see how effective the drug is and what side effects occur. The goal …
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC